Minaris Regenerative Medicine to expand its cell & gene therapy manufacturing capacity
The expansion will entail building two new facilities - one in Germany, the other in Japan.
Global contract development and manufacturing organization (CDMO) for cell and gene therapies, Minaris Regenerative Medicine, is set to invest 64.5 million USD to significantly expand its facilities in Europe and Asia.
A new state-of-the-art facility will be built in the proximity of the existing site in Ottobrunn near Munich, Germany with a total investment of 40.7 million USD.
The new facility will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing, as well as development services for cell and gene therapies.
The multistorey building with a total of 6,650 m2 will initially more than double Minaris’ existing capacity in Europe by providing additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space. It will have a modular design with the possibilities to go from single room to ball room design and to flexibly change between grade B and grade C configuration.
The new facility is expected to be operational early 2023 and will allow for additional expansion of cleanrooms according to client demand and specifications, thus more than tripling the current cleanroom capacity.
A new facility will also be established adjacent to the existing facility in Yokohama, Japan allowing for an additional 4,000 m2 which will double the capacity for commercial manufacturing of regenerative medicine.
The new facility is scheduled to start operations in October 2022. The investment of 23.8 million USD is part of a strategy to establish a center for cancer immunotherapy and somatic stem cells.
The European and Asian expansions complement the opening of the new commercial facility in Allendale, New Jersey, USA announced in January this year.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance